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Abstract
Objectives Advanced oral cancer is a major public health con-
cern because of a lack of effective prevention and treatment.
Triptolide (TPL), a diterpenoid triepoxide derived from the
Chinese herb Tripterygium wilfordii, has been demonstrated
to possess strong anticancer properties. In this study, we in-
vestigated whether TPL exerts anticancer effects on the tumor
microenvironment of head and neck squamous cell carcinoma
(HNSCC).
Materials and methods Human macrophage-like U937 cells
were co-inoculated with oral cancer SAS cells in a noncontact
transwell coculture system. Cytokine expression was detected
using ELISA, and cell proliferation was detected using meth-
ylene blue. RNA levels were detected using qPCR. Protein
levels were detected using Western blot analysis. In vivo ex-
periments involved using xenografted NOD/SCID mice.
Results Our results demonstrated that TPL inhibited the
growth of SAS cells co-inoculated with U937 cells in vitro
and in vivo. TPL inhibited the invasion, migration ability, and
angiogenesis of SAS cells co-inoculated with U937 cells.
Expression of cytokines IL-6, IL-8, and TNF-α was induced
by co-inoculation, but TPL repressed their expression.
Conclusion TPL suppressed the expression of cytokines IL-6,
IL-8, and TNF-α, as well as tumor growth, invasion, migra-
tion, and angiogenesis in the co-inoculation of human tongue
cancer cells with macrophage-like U937 cells.
Clinical relevance TPL is a potential candidate among novel
chemotherapeutic agents or adjuvants for modulating tumor-
associated macrophages in a tumor microenvironment of
HNSCC.
Keywords Triptolide . Chemoprevention . Co-inoculate .
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Introduction
Oral squamous cell carcinoma (OSQCC), the most common
of oral malignancies, is a type of head and neck squamous cell
carcinoma (HNSCC), which is the sixth most prevalent ma-
lignancy worldwide and the third most common cancer in
developing countries [1–5]. Concurrent chemoradiotherapy
has exhibited efficacy for organ preservation in head and neck
cancer, but has resulted in limited improvement in survival
rates. Discovering potential therapeutic drugs for advanced
oral cancer is thus paramount.
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Macrophages are widely distributed in the body, being pro-
duced by the differentiation of monocytes in tissues.
Macrophages participate in both innate and adaptive immunity
of vertebrate animals. In cancer patients, macrophages are often
observed to infiltrate the extracellular space around cancer cells
and are designated as tumor-associated macrophages (TAMs)
[6, 7]. A study revealed that the increase in TAMs in patients
suffering from head and neck cancer is associated with an in-
crease in histopathological grades and tumor angiogenesis [8].
Triptolide (TPL, C20H24O6, Fig 1a), a diterpenoid
triepoxide derived from the Chinese herb Tripterygium
wilfordii, exerts effects against oral cancer [9]. Moreover,
TPL exerts anticancer effects on multidrug-resistant KB-7D
and KB-tax cells that overexpress multidrug resistance-
associated protein (MRP), and the therapeutic effect of TPL
can be enhanced by combining it with 5-fluorouracil (5-FU)
[10]. Furthermore, we previously demonstrated that TPL re-
presses HER2 and suppresses the downstream PI3K/Akt-
signaling pathway [11]. Recently, we determined that TPL
combined with ionizing radiation treatment exerted synergis-
tic antitumor effects, particularly in vivo, and might be a
promising combined therapy for advanced oral cancer [12].
In the present study, we demonstrated the chemopreventive
therapeutic value of TPL. TPL suppressed the expression of
cytokines IL-6, IL-8, and TNF-α and repressed tumor growth,
invasion, migration, and angiogenesis in co-inoculation of hu-
man tongue cancer cells with macrophage-like U937 cells.
Materials and methods
Cells and chemicals
Human tongue squamous cell carcinoma cell line SAS was
provided by Dr. Jeng-Fan Lo [13]. The cell line U937 (histio-
cytic lymphoma) was obtained from the Bioresource
Collection and Research Center, Taiwan (derived from the
American Type Culture Collection). U937 cells (1 × 105
cells/mL) were differentiated to macrophage-like U937 cells
by exposing them to 200 ng/mL of phorbol 12-myristate 13-
acetate (PMA; Sigma, St. Louis, MO, USA). TPL
(Calbiochem, San Diego, CA, USA; purity more than or equal
to 95% as determined using high-performance liquid chroma-
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Fig. 1 Triptolide represses oral cancer cell proliferation in co-inoculation
with macrophage-like U937. a Chemical structure of Triptolide (TPL). b
SAS co-inoculated with PMA-treated U937 cells were treated with indi-
cated concentrations of TPL and then subjected to a methylene blue dye
assay for 24, 48, and 72 h to analyze proliferation of cells. c In vivo,
NOD/SCID mice bearing subcutaneous SAS co-inoculated with PMA-
treated U937 cells were treated with PBS (n = 5), TPL (n = 5; 0.15mg/kg/
day), and 5-FU (n = 3; 6 mg/kg/day). Mice bearing SAS cells were treated
with PBS as the control (n = 5). The average tumor weight of each group
was compared with that of the control (*P < 0.05 by Student’s t test). dNo
significant change was observed in mice body weight compared with that
of the control. e Diameters were measured twice a week for 45 days by
using a Vernier caliper, and the tumor volume was calculated using the
formula (L × W2)/2, whereW is the shortest diameter and L is the longest
diameter. Tumor volume compared with that of the control (*P < 0.05,
data were analysis by one-way ANOVA). All data are expressed as mean
±S.E.M
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stock and added to cells at the indicated concentrations. 5-
Fluorouracil (Sigma, F6627; purity more than or equal to
99 % as determined by high-performance liquid chromatog-
raphy) was dissolved in phosphate buffer saline (PBS).
Coculture in noncontact transwell system
Noncontact coculture transwell cell culture system was devel-
oped to study the cross biological activity of SAS and
macrophage-like U937 cells. We modified the previously study
methods [14]. In brief, the noncontact cocultured cells were
prepared as follows: SAS cells were plated on the bottom of a
six-well transwell cell culture system (pore size 0.4 μm) by
using the complete media and culture environment as described.
The U937 cells were cultured onto the membrane of transwell
cell culture inserts and allowed to grow overnight by PMA
treatment. On the next day, the cells were washed with media,
and the macrophage-like U937 cells cultured on membrane
transwell insert were placed into the six-well plate cultures con-
taining the SAS to initiate the experiment.
Growth inhibition assay
Cells in the logarithmic growth phase were cultured at a den-
sity of 1.5 × 105 cells/well in a 24-well plate. The cells were
exposed to various concentrations of TPL for 48 h. A methy-
lene blue dye assay was used to evaluate the effect of TPL on
cell growth, as described previously [9].
Invasion assay
SAS and U937 cells (2.5 × 104/chamber) were used for each
invasion assy. The invasion assay was performed using mod-
ified Boyden chambers covered with a polycarbonate
nucleopore membrane (Corning, Corning, NY, USA).
Precoated filters (6.5 mm in diameter, 8-μm pores, 35 μg of
Matrigel/chamber) were rehydrated, and 2.5 × 104 cells in a
medium were seeded into the upper part of each chamber.
After 24 h of incubation, nonmigratory cells on the upper
surface of the filter were wiped with a cotton swab, and mi-
grated cells on the lower surface of the filter were fixed and
stained with 0.125 % Commassie Blue in a methanol/acetic
acid/water mixture (45:10:45, v/v/v). Random fields were
counted under a light microscope.
Wound healing assay
After co-inoculationofSAScellswithU937cells, equalnumbers
of SAS cellswere replated at high densities in six-well plates and
grown overnight until reaching confluence. The next day, the
monolayer was wounded using a 200-μL pipette tip. The media
werechanged to removedebris, andthewoundwas imagedat0h,
and again after 4, 8, and 12 h. The average percentage of wound
healing was determined according to three measurements of the
wound area. For thewoundhealing assay, SAScellswere treated
with 10 nMTPL for 4, 8, and 12 h prior to wounding.
Vascular endothelial growth factor and cytokine analysis
conducted using ELISA
SAS and U937 cells (1.5 × 105) were grown in a complete
RPMI medium (containing 10 % FBS) in triplicate for 2 days
until they were 80–90 % confluent. After the cells were
washed with an FBS-free medium, they were allowed to grow
in a fresh RPMI medium containing 2 % FBS for 24 h. The
medium was harvested and detected for human vascular en-
dothelial growth factor (VEGF), IL-6, IL-8, and TNF-α by
using ELISA kits (all eBioscience). The results were
expressed as picogram per milliliter of the growth medium.
The final concentrations of VEGF, IL-6, IL-8, and TNF-α
were estimated by subtracting the obtained values from those
of the control.
Quantitative real-time PCR
Total RNAwas extracted from the cells by using TRIzol (Life
Technologies). Five micrograms of RNA from each sample
were then reverse-transcribed using Superscript III Reverse
Transcriptase (Life Technologies). Real-time quantitative PCR
(RT-qPCR) was performed using SYBR Green PCR Master
Mix (Life Technologies) and anABI 7500 Fast detection system
(Life Technologies). The RT-qPCR primers used were as fol-
lows:MMP-9 forward, 5′-TCTTCCAGTACCGAGAGAAAG-
3′; reverse, 5′- AGGATGTCATAGGTCACGTAG-3′; E-
cadherin forward, 5′-ACA GCC CCG CCT TAT GAT T-3′;
reverse, 5′-TCG GAA CCG CTT CCT TCA-3′; vimentin for-
ward, 5′-AGTCCACTGAGTACCGGAGAC-3′; reverse, 5′-
CATTTCACGCATCTGGCGTTC-3′); snail forward, 5′-CCC
CAA TCG GAA GCC TAA CT-3′; reverse, 5′-GCT GGA
AGG TAA ACT CTG GAT TAG A-3′; VEGF forward, 5′-
GCTCTACCTCCACCATGCCA-3 ′ ; r eve r s e , 5 ′ -
CACCACTTCGTGATGATTCTG-3′); IL-6 forward, 5′-CCT
TCC AAA GAT GGC TGA AA-3′; reverse, 5′-CAG GGG
TGG TTATTG CAT CT-3′); IL-8 forward, 5′-ATG ACT TCC
AAG CTG GCC GTG-3′; reverse, 5′-TCT CAG CCC TCT
TCA AAA ACT-3′; TNF-α forward, 5′-AGG CGG TGC
TTG TTC CTC A-3′; reverse, 5′-GTT CGA GAA GAT GAT
CTG ACT GCC-3′; GAPDH forward, 5′-GGA AGG TGA
AGG TCG GAG TCA-3′; reverse, 5′-GTC ATT GAT GGC
AAC AATATC CAC T-3′.
Protein extraction and Western blot analysis
The cells were lysed directly in an RIPA buffer (Millipore) sup-
plementedwithproteaseandphosphatase inhibitors (Sigma).The
relative protein concentration was determined using a BCA
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protein assay kit (Thermo Scientific). For each lane of 8 to 10%
SDS–PAGEgel, 50μg of cell lysate proteinwas loaded, separat-
ed,and transferredontoapolyvinyldifluoride (PVDF)membrane
(Millipore). Themembraneswere then probed using specific an-
tibodies against Matrix metallopeptidase 9 (MMP-9) (Abcam,
ab38898), E-cadherin (BD Biosciences, 610,181), vimentin
(Abcam, ab92547), snail protein (Cell Signaling, #3879), and
β-actin (BioVision, 3598–100).
Xenograft tumor model
Six-week-old NOD.CB17 Prkdcscid/J (National Laboratory
Animal Center, Taiwan) mice were maintained in a
microisolator in pathogen-free conditions. The mice were divid-
ed into four groups; each mouse in each group (n = 5; 5-FU,
n = 3) was subcutaneously injected with 2 × 106 of both SAS
and SAS cocultured with macrophage-like U937 cells. Three
days later, the mice in each group were further treated with
TPL (0.15 mg/kg/day) and 5-FU (12 mg/kg/day), and a vehicle
control (PBS) was then separately administered to the groups
through intraperitoneal (ip) injection. The size of the
transplanted tumors was measured using gauged calipers twice
a week, and the tumor volume was calculated using the follow-
ing formula: volume (V) = 1/2 × (length × width2). At the end of
the treatment, the mice were sacrificed, and the tumors were
removed, weighed, and photographed. The experiments were
conducted in accordance with institutional guidelines and were
approved by NDMC’s Institutional Animal Care and Use
Committee (approval number: IACUC-14-048).
Statistical analyses
All data were expressed as mean ± S.E.M. (standard error of
the mean) of at least three determinations, unless otherwise
stated. The differences between the two groups were deter-
mined using the Student’s t test or one-way ANOVA.
Results
Triptolide represses oral cancer cell proliferation
in co-inoculation with macrophage-like U937 cells, both
in vitro and in vivo
Tumor-associated macrophages induce the proliferation of can-
cer. We first tested whether TPL inhibited the growth of SAS
cells co-inoculated with macrophage-like U937 cells. We then
cocultured SAS cells with PMA-treated U937 cells in a noncon-
tact system. After 24, 48, and 72 h, the growth was inhibited
after treatment with various concentrations (0, 12.5, 25, 50, and
100 nM) of TPL, and the cell survival proportion was 100, 81.7,
50.3, 38.1, and 31.1 % at 24 h, respectively (Fig. 1b).
To further assess the therapeutic effect of TPL in vivo, we
established a xenograft tumor model in which SAS oral cancer
cells were co-inoculated with PMA-treated U937 cells. Tumor-
bearing mice were randomly divided into four groups and treat-
ed with a vehicle (PBS) or TPL alone (0.15 mg/kg/day); 5-FU
was used as the positive control (Fig. 1c). SAS co-inoculated
with PMA-treated U937 cell xenografts treated with TPL were
weighed (0.46 ± 0.28 g) and compared with the control group
(1.88 ± 0.21 g) (P = 0.0005; <0.05 vs control). Xenografts from
the TPL-treated group decreased 75.79 % in weight (Fig. 1c).
The body weight of the mice was monitored at 3-day intervals
throughout the experiment; the control group was 23.2 ± 2.2 g,
and the treated group was 24 ± 0.9 g. No significant change in
mouse body weight was observed compared with that of the
control (Fig. 1d). However, dynamically measuring tumor vol-
ume revealed that TPL exerted an inhibitory effect on xenografts
of SAS co-inoculated with U937 cells (Fig. 1e) (P = 0.0200,
0.0066, 0.0063, 0.0068, 0.0078, 0.0032; <0.05 vs untreated
control). These results revealed that TPL was effective against
SAS co-inoculated with macrophage-like U937 cells both in
vitro and in vivo.
Triptolide represses the invasive ability of oral cancer cells
in co-inoculation with macrophage-like U937 cells
For the invasion assay, the upper parts of the transwells were
coated with Matrigel. Adding TPL resulted in a reduction of
approximately 80 % for the penetration of both SAS and
PMA-treated U937 cells through aMatrigel-coated membrane
compared with that of the control group (Fig. 2a). Treatment
with 0 and 10 nM TPL resulted in an SAS cell count of 100
and 17.5 ± 2.12 %, respectively (P = 0.0290; < 0.05 vs un-
treated control), and a PMA-treated U937 cell count of 100 %
and 10.05 ± 4.75 %, respectively (P = 0.0144; < 0.05 vs
untreated control) (Fig. 2a). Western blot analysis revealed
that MMP-9 was downregulated compared with that of the
control group. In SAS cells treated with 0 and 10 nM TPL,
MMP-9 protein expression levels were 100 and 87 ± 5.89 %,
respectively (Fig. 2B; P = 0.0354; < 0.05 vs untreated
control). In PMA-treated U937 cells treated with 0 and
10 nM TPL, MMP-9 protein expression levels were 100 and
59 ± 15.12 %, respectively (Fig. 2b; P = 0.0185; <0.05 vs
untreated control). Total RNAwas isolated, and RT-PCR anal-
yses of MMP-9 were performed. GAPDH was used as an
internal control for RT-PCR. In TPL-treated cells, MMP-9
expression exhibited a decrease of approximately 50 % com-
pared with that of the control (Fig. 2c). In SAS cells treated
with 0 and 10 nM TPL, MMP-9 expression levels changed
145.24- and 88.07-fold, respectively (Fig. 2c; P = 0.0063;
<0.05 vs untreated control). In PMA-treated U937 cells treat-
ed with 0 and 10 nM TPL, MMP-9 expression levels changed
28.56- and 1.82-fold, respectively (Fig. 2c; P = 0.0055; <0.05
vs untreated control).
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Triptolide represses the migration ability of oral cancer
cells in co-inoculation with macrophage-like U937 cells
For the wound healing assay, cells were incubated in a six-
well plate and treated with TPL for 4 h. Images of the wound
were captured under ×100 magnification by using a micro-
scope. Cell migration was significantly decreased by TPL
treatment compared with that of the control group, and the
wound was imaged at 0 h and again after 4, 8, and 12 h
(Fig. 3a). Western blot analysis revealed that E-cadherin was
upregulated and vimentin was downregulated compared with
those of the control group. In cells treated with 0 and 10 nM
TPL, E-cadherin protein expression levels were 133 ± 4.32
and 100 %, respectively (P = 0.0004; <0.05 vs untreated con-
trol), whereas vimentin protein expression levels were
81.7 ± 5.19 and 100 %, respectively (Fig. 3b; P = 0.0075;
<0.05 vs untreated control). GAPDH was used as an internal
control for RT-PCR. Q-PCR revealed that compared with
those of the control, E-cadherin exhibited 1.6- and 4.6-fold
expression in cells treated with 0 and 10 nMTPL, respectively
(P = 0.0076; <0.05 vs untreated control), whereas vimentin
exhibited 653- and 120-fold expression in cells treated with 0
and 10 nM TPL, respectively (P = 0.0051; <0.05 vs untreated
control) (Fig. 3b). Snail protein was downregulated compared
with that of the control group. In cells treated with 0 and
10 nM TPL, the expression levels of snail protein were 100
and 92.1 ± 1.54 %, respectively (Fig. 3c; P = 0.0020; <0.05 vs
untreated control). Q-PCR revealed that compared with that of
the control, snail protein exhibited 27.8- and 5.8-fold expres-
sion in the cells treated with 0 and 10 nM TPL, respectively
(Fig. 3c; P = 0.0014; < 0.05 vs untreated control).
Triptolide represses the angiogenesis ability of oral cancer
cells in co-inoculation with macrophage-like U937 cells
In co-inoculation with PMA-treated U937 cells, VEGF
was downregulated in the TPL-treated group compared
with that of the control group (co-inoculation U937 cells).
In cells treated with 0 and 10 nM TPL, VEGF exhibited
expression protein levels of 100 and 74 ± 8.48 %, respec-
tively (Fig. 4a). Total RNA was isolated, and RT-PCR
analyses of VEGF were performed. GAPDH was used as
an internal control for RT-PCR. We determined that VEGF
was predominantly secreted by SAS cells (not by PMA-
Fig. 2 Triptolide represses oral cancer cell invasive ability in co-
inoculation with macrophage-like U937. a Through the invasion assay,
both SAS and PMA-treated U937 revealed a decreased invasive ability
after TPL treatment compared with that of the control. b Effects of TPL
onMMP-9 expression through aWestern immunoblotting assay. c Effects
of TPL on MMP-9 expression according to Q-PCR (P < 0.05 by
Student’s t test)
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treated U937 cells) in the co-inoculation of both cell lines.
According to the Q-PCR results, TPL-treatment resulted
in a VEGF reduction of approximately 90 % compared
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Fig. 3 Triptolide represses oral cancer cell migration ability in co-
inoculation with macrophage-like U937. a Through a wound healing
assay, SAS cells demonstrated a decreased migration ability after TPL
treatment compared with that of the control. Images of the wound were
captured under ×100 magnifications by using a microscope. b Effects of
TPL on E-cadherin and vimentin expression through a Western
immunoblotting assay. After 10 nM TPL treatment for 48 h, E-cadherin
increased and vimentin expression decreased compared with those of the
control. c After 10 nM TPL treatment for 48 h, snail protein expression














































































Fig. 4 Triptolide represses oral cancer cell angiogenesis ability in co-
inoculation with macrophage-like U937. a Effects of TPL on VEGF
expression by ELISA. After 10 nM TPL treatment for 48 h, VEGF
protein expression decreased compared with that of the control. b
Effects of TPL on VEGF expression by Q-PCR. The data revealed the
VEGF is a major expression from SAS and downregulated by TPL
treatment compared with that of the control (P < 0.05 by Student’s t test)
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Triptolide represses cytokine expression in co-inoculation
of SAS cells with macrophage-like U937 cells
Cytokines IL-6, IL-8, andTNF-αwereabundantlysecreted in the
co-inoculation of SAS cells with PMA-treated U937 cells, but
TPL repressed these cytokines according to the results of the
ELISA (Fig. 5a). In cells treated with 0 and 10 nM TPL, IL-6
concentrations were 557 and 282 pg/mL, respectively; IL-8 con-
centrations were 175 473 and 24 495 pg/mL, respectively; and
TNF-α concentrationswere10 440 and1316pg/mL, respective-
ly. According to the Q-PCR results, IL-6 was predominantly se-
cretedbySAScells,whereas IL-8andTNF-αwerepredominant-
ly secreted by PMA-treated U937 cells (Fig. 5b). All these cyto-
kines were repressed by TPL in contrast to the control. The Q-
PCR results revealed that in cells treated with 0 and 10 nMTPL,
IL-6 exhibited 60- and 10-fold expression, respectively, IL-8 ex-
hibited 250 000- and 13 000-fold expression, respectively, and
TNF-α exhibited 90 000- and 70 000-fold expression, respec-
tively, comparedwith those of the control (SAS) (Fig. 5b).
Discussion
Our previous study revealed that TPL can inhibit tumor
growth by inducing apoptosis in cancer cells [9]. In the present
study, we demonstrated that TPL can inhibit SAS cell growth
in co-inoculated with macrophage-like U937 cells, in vitro
and in vivo (Fig. 1). A previous study demonstrated that PC-
3 prostate cancer cells and U937 promonocytic cells enhanced
tumor growth and increased tumor angiogenesis [15]; they
determined that IL-4 was a crucial cytokine regulating the
differentiation of monocytes and macrophages into TAMs in
prostate cancer cells. Stimulating U937 cells with IL-4 result-
ed in an increase in tumor growth in vivo and stimulated
angiogenesis within the tumor bed.
A study revealed that MMPs play a key role for tumor
growth, progression, metastasis, and angiogenesis [16]. Both
MMP-2 andMMP-9 are mainly involved in tumor metastasis.
In human fibrosarcoma cells (HT-1080), TPL can modulate







Fig. 5 Triptolide represses these cytokines expression in SAS co-
inoculation with macrophage-like U937. a The cytokine expression of
IL-6, IL-8, and TNF-α were induced by co-inoculation, and the TPL
(10 nM) repressed these cytokines expression by ELISA. b IL-6 was
predominantly secreted from SAS cells; IL-8 and TNF-α were
predominantly secreted from U937, detected using Q-PCR. All these
cytokines were repressed by TPL compared with those of the control
(P < 0.05 by Student’s t test)
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can reduce invasiveness by directly lowering MMP-9 gene
expression and activity [17]. Here, we demonstrated that
TPL inhibited not only the invasive ability of SAS cells but
also the invasive ability of macrophage-like U937 cells in co-
inoculation (Fig. 2a). Both protein (Fig. 2b) and gene (Fig. 2c)
expressions were downregulated by TPL (10 nM) treatment
for 24 and 48 h.
In ovarian cancer cells SKOV3 and A2780, TPL (15 nM)
inhibited cell migration but enhanced E-cadherin expression
in tumors in a dose-dependent manner [18]. In the present
study, we demonstrated that TPL inhibited the migratory abil-
ity of SAS cells in co-inoculation with macrophage-like U937
cells (Fig. 3a). E-cadherin was upregulated and vimentin was
downregulated after TPL treatment of SAS cells (Fig. 3b).
Snail protein was also downregulated after TPL treatment of
SAS cells (Fig. 3c). These epithelium-mesenchymal transi-
tion-related proteins were modulated by TPL treatment and
exhibited consistent tumorigenicity.
VEGF is a signal protein produced by cells that stimulates
angiogenesis. In pancreatic cancer cells (PANC-1), TPL de-
creased the expression of VEGF both in vitro and in vivo in a
time- and concentration-dependent manner [19]. We deter-
mined that VEGF increased substantially in a culture medium,
and TPL decreased VEGF levels in co-inoculation with
macrophage-like U937 cells (Fig. 4a). We also demonstrated
that VEGF was predominantly secreted by SAS cells (not by
macrophage-like U937 cells), according to the Q-PCR results
(Fig. 4b).
Cancer cells produce several cytokines that act on the
surrounding interstitial cells, which can build a microen-
vironment for the growth and metastasis of cancer cells.
We determined that cytokines IL-6, IL-8, and TNF-α
were abundantly secreted in the co-inoculation of SAS
cells with macrophage-like U937 cells, as detected using
an ELISA (Fig. 5a). The Q-PCR results demonstrate that
IL-6 was predominantly secreted by SAS cells (not by
macrophage-like U937 cells) (Fig. 5b). IL-6 is a cyto-
kine secreted by T cells and macrophages to stimulate
immune response, but elevated expression of IL-6 has
been detected in multiple tumors [20]. Many studies
have reported a high concentration of IL-6 in the serum
of patients with head and neck cancer and have associ-
ated high IL-6 levels with a poor prognosis [21, 22].
These results have suggested that IL-6 is likely to in-
vade and metastasize, as well as promote immune unre-
sponsiveness (Figs. 2 and 3).
The Q-PCR results also demonstrate that IL-8 was predom-
inantly secreted by macrophage-like U937 cells (not by SAS
cells) (Fig. 5b). IL-8 is a neutrophil chemotactic factor pro-
duced by macrophages and epithelial cells; it induces chemo-
taxis and phagocytosis in target cells and is a potent promoter
of angiogenesis. IL-8 protein typically increases in the serum
of cancer patients and affects the proliferation, migration,
angiogenesis, and metastasis of cancer cells [20, 23, 24]
Local IL-8 production is related to malignancies and tumor
progression; thus, elevated IL-8 levels in serum are indicative
of a malignant process. High IL-8 levels are typically ob-
served in high-grade peritumoral fluids rather than in low-
grade tumors and benign conditions. Hence, IL-8 in
peritumoral fluid must be considered when assessing tumor
character and monitoring tumor progression or remission
status.
In this study, TNF-α was predominantly secreted by
macrophage-like U937 cells (not by SAS cells), according to
the Q-PCR results (Fig. 5b). TNF-α is the most critical proin-
flammatory cytokine involved in cell growth, differentiation,
and apoptosis [25, 26] and has been reported to play a critical
role in carcinogenesis [26]. Consistent with these reports, nu-
merous studies have indicated that chronic inflammation and
proinflammatory mediators including TNF-α might increase
the risk of malignancy [27].
TAMs have been implicated in promoting tumor growth
and progression. Thus, macrophages are at the center of the
invasion microenvironment and are a crucial drug target for
cancer therapy [6]. Macrophages do not harbor malignant mu-
tations and therefore exhibit a stable genome; thus, they are
unlikely to develop drug resistance. This makes them an op-
timal target for cytostatic treatment of tumor progression to
malignancy, using small molecule inhibitors of selected mac-
rophage functions. Studying the signaling pathways that allow
macrophages to contribute to tumor progression can lead to
new insights into the evolution of the microenvironments
supporting invasion and metastasis, thereby providing targets
for anticancer therapies [6].
This study indicates the potential anticancer role of TPL, a
compound that exhibited antitumor effects in co-inoculation
of human tongue cancer cells with macrophage-like U937
cells. Thus, TPL is a potential candidate among novel chemo-
therapeutic agents or adjuvants for modulating TAMs in a
tumor microenvironment.
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